Milnocor (Milrinone)

Milrinone, the active ingredient in Milnocor, is a phosphodiesterase‑3 inhibitor presented as an intravenous solution for intravenous use. It is used to improve cardiac output in patients with acute decompensated heart failure or cardiogenic shock. GNH USA supplies Milnocor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Milnocor is a phosphodiesterase‑3 inhibitor indicated for conditions affecting cardiac performance.

Acute decompensated heart failure: enhances myocardial contractility and reduces afterload to improve cardiac output. Cardiogenic shock: provides rapid inotropic support to restore systemic perfusion. Low cardiac output syndrome after cardiac surgery: stabilizes hemodynamics during postoperative recovery.

Milnocor may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypotension: reduction in blood pressure, especially with rapid infusion. - Tachyarrhythmias: premature ventricular beats or supraventricular tachycardia. - Headache: mild to moderate intensity. - Nausea or vomiting: gastrointestinal discomfort. - Flushing: transient warmth and redness of skin. - Thrombocytopenia: mild decrease in platelet count.

Serious or Rare Side Effects: - Severe hypotension: profound drop in blood pressure requiring intervention. - Ventricular arrhythmias: life‑threatening rhythm disturbances. - Myocardial ischemia: chest pain due to reduced coronary perfusion. - Anaphylactic reactions: rare but potentially fatal hypersensitivity. - Pulmonary edema: fluid accumulation in lungs. - Liver enzyme elevation: abnormal hepatic function tests.

Milnocor requires careful monitoring and specific safety measures before and during therapy.

Cardiac monitoring: continuous ECG and hemodynamic assessment are essential. Renal impairment: dose adjustment may be needed in patients with reduced clearance. Severe hypotension: avoid use in patients with markedly low blood pressure. Concomitant vasodilators: use cautiously with other agents that lower vascular tone. Electrolyte balance: monitor potassium and magnesium levels to reduce arrhythmia risk. Store at room temperature: keep in original container, protect from moisture and light.

Milnocor can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid): - Other phosphodiesterase‑3 inhibitors: additive inotropic and vasodilatory effects may cause severe hypotension. - Potent vasodilators (e.g., nitroglycerin): risk of profound blood pressure drop. - Anti‑arrhythmic agents (e.g., amiodarone): increased likelihood of ventricular arrhythmias.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt the desired inotropic response. - Diuretics: electrolyte shifts can heighten arrhythmia risk. - ACE inhibitors or ARBs: additive blood pressure lowering effect.